AAV Vectors Deliver AP-4 Subunits for HSP Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for AP-4-associated hereditary spastic paraplegia (HSP) are lacking, and there is a need for effective therapies to improve patient outcomes as existing methods do not address the progressive nature of the disease effectively.
Innovation Solution
Development of expression vectors, specifically adeno-associated virus (AAV) vectors, that encode nucleic acid molecules for the AP-4 complex subunits (AP4B1, AP4E1, AP4M1, and AP4S1) to be used in mammalian neurons, enabling functional replacement of dysfunctional proteins and potential treatment of AP-4-HSP symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adeno-associated virus (AAV) vectors are used to deliver nucleic acid molecules encoding AP-4 complex subunits, then functional replacement of dysfunctional proteins is achieved, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent uses AAV vectors as intermediary carriers to deliver nucleic acid molecules encoding AP-4 complex subunits into neurons. The viral vector acts as a mediator that facilitates gene transfer without integrating into the genome, enabling functional replacement of dysfunctional proteins through extrachromosomal storage and expression of the therapeutic genes.
2Object-affected harmful factors
If AAV vectors are used for gene delivery, then immune response is reduced compared to retroviral or lentiviral vectors, but the efficiency of gene integration and long-term expression is limited
Solution Approach 1:
The patent extracts the integrase function from the AAV vector system, deliberately avoiding genome integration. Instead, the nucleic acid molecules are maintained as extrachromosomal elements, which eliminates immune responses associated with integration while still achieving sustained gene expression through stable maintenance of the therapeutic transgenes in neuronal cells.
3Reliability
If existing treatment methods are used for AP-4-HSP, then disease progression cannot be effectively addressed, but no effective therapy is currently available
Solution Approach 1:
The patent employs preliminary action by delivering nucleic acid molecules encoding functional AP-4 complex subunits before significant neurological damage occurs. The AAV vectors establish therapeutic gene expression in advance, preventing disease progression rather than treating established symptoms, which is particularly important for this progressive neurodegenerative condition.
Data Source
AI summary
This disclosure concerns transcription cassettes comprising nucleic acid molecules comprising a nucleotide sequence encoding AP-4 subunits; vectors comprising said transcription cassettes; pharmaceutical compositions comprising said vector; and vectors or compositions for use in the treatment of AP-4-Hereditary Spastic Paraplegia.